Pharmacotherapy for Schizophrenic Drug Users - 6
Phase 2
Completed
- Conditions
- Substance-Related DisordersCocaine-Related DisordersShcizophrenia
- Registration Number
- NCT00000281
- Lead Sponsor
- Yale University
- Brief Summary
The purpose of this study is to evaluate maintenance neuroleptics for Schizophrenic patients who are cocaine abusers.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- Not specified
Inclusion Criteria
Not provided
Exclusion Criteria
Not provided
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Drug use Retention Schizophrenic symptoms Psychological symptoms
- Secondary Outcome Measures
Name Time Method
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular mechanisms underlie the efficacy of maintenance neuroleptics in treating schizophrenia with cocaine use disorder?
How do maintenance neuroleptics compare to standard-of-care antipsychotics for schizophrenic patients with cocaine addiction?
Are there specific biomarkers that predict response to neuroleptic maintenance therapy in comorbid schizophrenia and cocaine dependence?
What adverse events are associated with neuroleptic maintenance in schizophrenia patients with substance use disorders and how are they managed?
What combination therapies or alternative pharmacological approaches have been explored for treating schizophrenia and cocaine abuse comorbidity?
Trial Locations
- Locations (1)
VA Connecticut Healthcare System
🇺🇸New Haven, Connecticut, United States
VA Connecticut Healthcare System🇺🇸New Haven, Connecticut, United States